SEC62 and head and neck cancer: Since almost all melanomas investigated in our study showed a strong SEC62 expression, with IRS values between 9 and 12, the aforementioned therapeutics that have been successfully tested in SEC62-overexpressing head and neck cancer xenografts in vivo are promising targets for new therapeutic approaches for this difficult-to-treat cancer entity.